Updated recommendations for the treatment of light-chain amyloidosis from the Swiss Amyloidosis Network

Since the publication of the first Swiss recommendations on systemic light-chain amyloidosis in 2020, treatment strategies have evolved. As a result of the third joint meeting of the Swiss Amyloidosis Network, a multidisciplinary and multicentre Swiss clinical consortium, in 2024, recommendations fo...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Swiss medical weekly Ročník 155; číslo 7; s. 4219
Hlavní autori: Rieger, Max J., Flammer, Andreas J., Gerull, Sabine, Pabst, Thomas, Auner, Holger W., Samii, Kaveh, Hitz, Felicitas, Mey, Ulrich, Ballova, Veronika, Battegay, Raphael, Melli, Giorgia, Benz, Dominik, Yakupoglu, Yakup, Gräni, Christoph, Schläger, Regina, Hugelshofer, Sarah, Studer, Annina, Oechslin, Luca, Bakula, Adam, Suter, Thomas M., Leo-Stickelberger, Julia, Averiamo, Manuela, Fehr, Thomas, Jung, Hans H., Laptseva, Natallia, Manka, Robert, Rüfer, Axel, Schmidt, Adrian, Seeger, Harald, Müllhaupt, Beat, Stämpfli, Simon F., De Ramon Ortiz, Carmen, Théaudin, Marie, Gerber, Bernhard, Schwotzer, Rahel
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: Switzerland SMW supporting association (Trägerverein Swiss Medical Weekly SMW) 17.07.2025
Predmet:
Antibodies, Monoclonal - therapeutic use
Bortezomib - therapeutic use
Cyclophosphamide - therapeutic use
Dexamethasone - therapeutic use
Humans
Immunoglobulin Light-chain Amyloidosis - drug therapy
Immunoglobulin Light-chain Amyloidosis - therapy
Practice Guidelines as Topic
Switzerland
Switzerland
ISSN:1424-3997, 1424-3997
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Since the publication of the first Swiss recommendations on systemic light-chain amyloidosis in 2020, treatment strategies have evolved. As a result of the third joint meeting of the Swiss Amyloidosis Network, a multidisciplinary and multicentre Swiss clinical consortium, in 2024, recommendations for the treatment of light-chain amyloidosis were updated. They discuss the role of the new standard first-line protocol Daratumumab, Cyclophosphamide, Bortezomib, Dexamethasone (Dara-CyBorD), the timing and indication of high-dose treatment and potential second-line strategies as well as emerging treatment options, with a special focus on multidisciplinary supportive care measures. The update represents a synopsis of current evidence and expert consensus and intends to provide general treatment guidance tailored to the Swiss healthcare system. Nonetheless, treatment decisions should always be personalised and involve a multidisciplinary approach. This update replaces the previous “therapeutic recommendations” while the previous “diagnostic recommendations” remain valid.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1424-3997
1424-3997
DOI:10.57187/s.4219